KMPH [delisted] KemPharm Inc

Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals

NASDAQ | Common Stock

Price
$4.97
Increased by +0.61%
Dollar volume (20D)
1.36 M
ADR%
6.10
Shares float
31.26 M
Shares short
1.37 M [4.39%]
Shares outstanding
34.50 M
Market cap
200.47 M
Beta
2.16
Price/earnings
N/A
20D range
4.85 6.44
50D range
4.05 6.44
200D range
4.05 6.92

Zevra Therapeutics, Inc., a rare disease therapeutics company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.

The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.

Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH).

The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate.

It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial.

In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

Zevra Therapeutics, Inc. has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA.

The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023.

Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 10, 23 -0.34
Decreased by -580.00%
-0.15
Decreased by -133.68%
Mar 7, 23 -0.26
Decreased by -225.00%
-0.17
Decreased by -52.94%
Nov 9, 22 -0.19
Decreased by -280.00%
-0.13
Decreased by -46.15%
Aug 11, 22 -0.70
Decreased by -433.33%
-0.12
Decreased by -483.33%
May 12, 22 -0.05
Increased by +90.74%
-0.05
Mar 30, 22 -0.08
Increased by +92.52%
-0.07
Decreased by -14.29%
Nov 10, 21 -0.05
Increased by +92.19%
-0.07
Increased by +28.57%
Aug 12, 21 0.21
Increased by +31.25%
0.23
Decreased by -8.70%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 23 2.88 M
Decreased by -27.39%
-340.00
Increased by +99.98%
Decreased by -0.01%
Increased by +99.97%
Dec 31, 22 2.32 M
Decreased by -10.19%
-9.02 M
Decreased by -242.35%
Decreased by -389.00%
Decreased by -281.18%
Sep 30, 22 2.87 M
Increased by +46.26%
-6.62 M
Decreased by -276.12%
Decreased by -230.20%
Decreased by -157.16%
Jun 30, 22 1.30 M
Decreased by -89.15%
-24.04 M
Decreased by -487.59%
Decreased by -1.85 K%
Decreased by -3.67 K%
Mar 31, 22 3.96 M
Decreased by -67.28%
-1.86 M
Increased by +81.90%
Decreased by -47.01%
Increased by +44.67%
Dec 31, 21 2.58 M
Increased by +9.13%
-2.63 M
Increased by +45.74%
Decreased by -102.05%
Increased by +50.28%
Sep 30, 21 1.97 M
Increased by +2.08%
-1.76 M
Increased by +41.54%
Decreased by -89.52%
Increased by +42.73%
Jun 30, 21 11.99 M
Increased by +73.51%
6.20 M
Increased by +622.12%
Increased by +51.75%
Increased by +316.19%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY